

NIGERIA - Pneumococcal Vaccine support

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Nigeria					
2. Grant number: 13-NGA-08a-Y; 1820-NGA-12a-X					
3. Date of Decision Letter: 21 December 2017					
4. Date of the Partnership Framework Agreement: 9 January 2014					
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine					
6. Vaccine type: Pneumococcal					
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV10), 4 dose(s) per vial , LIQUID					
8. Programme duration¹: 2014 - 2020					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2014-2017	2018	2019	2020	Total ²
Programme Budget (US\$)	192,237,642 ³	18,379,000	35,670,500	30,776,500	277,063,642
10. Vaccine introduction grant (in US\$) / Product switch grant: US\$ 5,602,500 out of which US\$1,901,879 disbursed on 3 December 2014 and US\$ 2,015,539 paid on 26 February 2016. Product switch grant not requested by country.					
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴					
Type of supplies to be purchased with Gavi funds in each year	2014-2017	2018			
Number of Pneumococcal vaccines doses		5,138,800			
Annual Amounts (US\$)	US\$ 192,237,642 ⁵	US\$18,379,000			
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
13. Self-procurement: Not applicable.					
14. Co-financing obligations: Reference code: 1820-NGA-12a-X-C According to the co-financing policy, the Country falls within the group Accelerated transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

Type of supplies to be purchased with Country funds in each year	2018	2019	2020
Number of vaccine doses	4,527,200	12,950,800	16,266,000
Number of AD syringes	4,468,100		
Number of safety boxes	49,175		
Value of vaccine doses (US\$)	US\$13,807,400		
Total co-financing payments (US\$) (including freight)	US\$14,093,500	US\$40,352,000	US\$50,682,000
15. Operational support for campaigns: Not applicable			
16. Additional reporting requirements:			
Reports and other information		Due dates	
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.		May 2018	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.		To be agreed with Secretariat	
17. Financial clarifications: Country shall provide the following clarifications to Gavi*: Not applicable <i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i>			
18. Other conditions: Not applicable.			

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
21 December 2017